Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose TherapyGema Mateo, Jesús F. San Miguel, María-Ángeles Montalbán et al.|Journal of Clinical Oncology|2008Cited by 210
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patientsBruno Paiva, María‐Belén Vídriales, Gema Mateo et al.|Blood|2009Cited by 75
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.María‐Victoria Mateos, Jesús F. San Miguel, Albert Oriol et al.|Blood|2009Cited by 45
Clinical applicability and prognostic significance of molecular response assessed by fluorescent‐<scp>PCR</scp>of immunoglobulin genes in multiple myeloma. Results from a<scp>GEM</scp>/<scp>PETHEMA</scp>studyJoaquín Martínez‐López, Marisa Martín, Rosa Ayala et al.|British Journal of Haematology|2013Cited by 29
Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma.Joaquín Martínez‐López, Juan José Lahuerta, Ramón García‐Sánz et al.|Journal of Clinical Oncology|2013Cited by 2